Physician profile
Don Esprit
NPI 1669733986
$3,987.38
in general payments reported to CMS, 2019-2025
20 companies · $912 in 2025
The $912 reported for 2025 was more than what 76% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.99 · 2021: $314 · 2022: $693 · 2023: $1,236 · 2024: $733 · 2025: $912.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,861 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,860.79 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $774.24 | 2021-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $577.60 | 2021-2025 | Farxiga, Lokelma |
| Amgen INC. | $419.69 | 2023-2025 | Krystexxa, Tavneos |
| Vifor Pharma, INC. | $294.31 | 2021-2025 | Veltassa |
| Fresenius USA Marketing, INC. | $242.64 | 2022-2025 | Velphoro, Korsuva, Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $216.36 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $215.28 | 2022-2023 | Acthar |
| Horizon Therapeutics Plc | $208.45 | 2023 | Krystexxa |
| Calliditas Therapeutics US INC. | $168.78 | 2022-2025 | Tarpeyo |
| Recor Medical INC | $149.29 | 2025 | Paradise Ultrasound Renal Denervation System |
| Limflow INC. | $134.62 | 2023 | Limflow System |
| Novartis Pharmaceuticals Corporation | $126.21 | 2023-2025 | |
| Mallinckrodt Enterprises LLC | $99.99 | 2019 | |
| Akebia Therapeutics INC | $92.64 | 2021-2024 | Auryxia, Vafseo |
| Ardelyx, INC. | $84.06 | 2023-2025 | Ibsrela |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $77.16 | 2024 | Jardiance |
| Cormedix INC. | $32.20 | 2024 | Defencath |
| Travere Therapeutics, INC. | $30.19 | 2025 | |
| Aurinia Pharma U.S., INC. | $25.88 | 2025 | Lupkynis |
| Daiichi Sankyo INC. | $17.79 | 2023 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Don Esprit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.